HomeInsulin Glargine And LixisenatideInsulin Glargine And Lixisenatide + Nonselective Beta Adrenergic Antagonists

Does Insulin Glargine And Lixisenatide Interact with Nonselective Beta Adrenergic Antagonists?

Insulin Glargine And Lixisenatide and Nonselective Beta Adrenergic Antagonists have a moderate drug interaction according to U.S. FDA drug labeling data. May increase or decrease blood glucose lowering effect and may blunt signs/symptoms of hypoglycemia. Dose adjustment and increased glucose monitoring may be required. The mechanism involves affects glucose metabolism and hypoglycemia awareness. Patients taking both medications should consult their healthcare provider before starting, stopping, or changing the dosage of either drug. This information is based on official FDA drug labeling sourced from OpenFDA and the NIH National Library of Medicine.

Severity
Moderate
Insulin Glargine And Lixisenatide Class
Insulin Analog
Management
Monitor for effects
Data Source
U.S. FDA via OpenFDA

How This Interaction Works

The interaction between Insulin Glargine And Lixisenatide and Nonselective Beta Adrenergic Antagonists occurs because affects glucose metabolism and hypoglycemia awareness. Clinically, this means may increase or decrease blood glucose lowering effect and may blunt signs/symptoms of hypoglycemia. dose adjustment and increased glucose monitoring may be required. This is classified as a moderate interaction. While it may not require stopping either medication, your healthcare provider should be aware you are taking both so they can monitor for potential effects and adjust treatment if necessary.

What To Tell Your Doctor or Pharmacist

If you are taking Insulin Glargine And Lixisenatide and your doctor is considering prescribing Nonselective Beta Adrenergic Antagonists (or vice versa), make sure to:

  • Inform your doctor and pharmacist of all current medications, including over-the-counter drugs and supplements
  • Ask whether the benefits of combining these medications outweigh the risks for your specific situation
  • Ask what symptoms to watch for that would indicate the interaction is causing problems
  • Ask whether any dosage adjustments are needed
  • Never stop or change either medication without first consulting your healthcare provider
💊 Insulin Glargine And Lixisenatide(Soliqua 100/33)+💊 Nonselective Beta Adrenergic Antagonists(Macuvite With Lutein)

Severity & Interaction Details

🟡
moderate
Be aware — moderate interaction
Documented interaction with manageable risk. May require dose adjustment or monitoring.
Severity scale
MinorContra
On record
Yes
Drug A class
Insulin Analog
Drug B class
Source
NLP:insulin glargine and lixisenatide

What this means in plain English

May increase or decrease blood glucose lowering effect and may blunt signs/symptoms of hypoglycemia. Dose adjustment and increased glucose monitoring may be required.

About Insulin Glargine And Lixisenatide and Nonselective Beta Adrenergic Antagonists

Insulin Glargine And Lixisenatide is an Insulin Analog. Nonselective Beta Adrenergic Antagonists is also sold under the brand name B-Caro-T. Insulin Glargine And Lixisenatide is given by injection under the skin.

What the FDA label says

"Affects glucose metabolism and hypoglycemia awareness"

📖 Source: NLP:insulin glargine and lixisenatide

Share this result:

WhatsAppText / SMSEmail
Also share on:XFacebook
Add more drugs
Check Insulin Glargine And Lixisenatide and Nonselective Beta Adrenergic Antagonists against your full medication list

Most patients take more than two medications. CDI checks every pair across up to 20 drugs simultaneously — including OTCs and common supplements.

Add more drugs →
Data integrity: Every interaction shown is extracted directly from official U.S. FDA drug labeling via openFDA and the U.S. National Library of Medicine (NIH) — no interactions are invented, inferred, or manually edited. Maintained by CheckDrugInteractions.com. See our methodology or report a correction at support@checkdruginteractions.com.

Data sourced from U.S. FDA drug labeling via openFDA and the NIH National Library of Medicine, supplemented with a small number of well-established interactions from curated clinical references. For informational purposes only. Always consult your pharmacist or physician.